An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure

PURPOSE: Glasdegib, an oral inhibitor of the Hedgehog signaling pathway, is approved in the United States in combination with low-dose cytarabine (LDAC) to treat patients with newly diagnosed acute myeloid leukemia (AML) ineligible to receive intensive chemotherapy. This population pharmacokinetic/p...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Swan, Shaik, Naveed, Chan, Geoffrey, Cortes, Jorge E., Ruiz-Garcia, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515941/
https://www.ncbi.nlm.nih.gov/pubmed/32885274
http://dx.doi.org/10.1007/s00280-020-04132-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515941/
https://www.ncbi.nlm.nih.gov/pubmed/32885274
http://dx.doi.org/10.1007/s00280-020-04132-x

Ejemplares similares